Tyra Biosciences, Inc. (TYRA)
$24.94-$1.19 (-4.55%) Today
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 7 | 92,120 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
44 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
 Rehan Verjee | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
| Susan Moran | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
 Jake Simson | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
 Adele M. Gulfo | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
| Robert J. More | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
| Stephen Michael Rothenberg | Grant or award | Stock Option (Right to Buy) | 13,160 | $0.00 | - | |
| Douglas J. Warner - Officer | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Douglas J. Warner - Officer | Grant or award | Stock Option (Right to Buy) | 85,000 | $0.00 | - | |
| Alan Fuhrman - Officer | Grant or award | Common Stock | 20,000 | $0.00 | - | |
| Alan Fuhrman - Officer | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Todd Harris - Officer | Grant or award | Common Stock | 79,000 | $0.00 | - | |
| Todd Harris - Officer | Grant or award | Stock Option (Right to Buy) | 265,000 | $0.00 | - | |
| Bhavesh Ashar - Officer | Grant or award | Common Stock | 15,013 | $0.00 | - | |
| Bhavesh Ashar - Officer | Grant or award | Stock Option (Right to Buy) | 50,295 | $0.00 | - | |
| Yuliya Rueb - Officer | Grant or award | Common Stock | 8,333 | $0.00 | - | |
| Yuliya Rueb - Officer | Grant or award | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Habib J. Dable | Grant or award | Stock Option (Right to Buy) | 44,400 | $0.00 | - | |
| Gilla Kaplan | Option exercise | Common Stock | 14,295 | $2.25 | $32K | |
| Gilla Kaplan | Option exercise | Common Stock | 53,172 | $2.25 | $120K | |
| Gilla Kaplan | Open-market sale | Common Stock | 14,295 | $36.97 | $529K | |
| Gilla Kaplan | Derivative | Common Stock | 53,172 | $37.75 | $2.01M | |
| Gilla Kaplan | Option exercise | Stock Option (Right to Buy) | 14,295 | $0.00 | - | |
| Gilla Kaplan | Option exercise | Stock Option (Right to Buy) | 53,172 | $0.00 | - | |
| Alan Fuhrman - Officer | Grant or award | Common Stock | 1,376 | $9.13 | $13K | |
| Todd Harris - Officer | Grant or award | Common Stock | 1,463 | $9.13 | $13K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 2,128 | $31.50 | $67K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 5,872 | $33.37 | $196K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 6,983 | $28.44 | $199K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 1,017 | $29.08 | $30K | |
| Robert J. More | Open-market sale | Common Stock | 10,000 | $25.00 | $250K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 8,000 | $22.64 | $181K | |
| Bhavesh Ashar - Officer | Grant or award | Stock Option (Right to Buy) | 300,000 | $0.00 | - | |
| Robert J. More | Open-market sale | Common Stock | 246,871 | $20.25 | $5.00M | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 75,633 | $16.07 | $1.22M | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 49,956 | $16.32 | $815K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 1,500 | $17.07 | $26K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 1,111 | $16.00 | $18K | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 110,228 | $16.02 | $1.77M | |
| Daniel Bensen - Officer | Open-market sale | Common Stock | 18,572 | $16.11 | $299K | |
| Alan Fuhrman - Officer | Grant or award | Common Stock | 701 | $9.13 | $6K | |
| Alan Fuhrman - Officer | Grant or award | Stock Option (Right to Buy) | 170,000 | $0.00 | - | |
| Daniel Bensen - Officer | Grant or award | Stock Option (Right to Buy) | 170,000 | $0.00 | - | |
| Douglas J. Warner - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| Todd Harris - Officer | Grant or award | Stock Option (Right to Buy) | 570,000 | $0.00 | - | |
| Gilla Kaplan | Open-market sale | Common Stock | 10 | $10.35 | $104 | |
| Gilla Kaplan | Open-market sale | Common Stock | 9,568 | $9.78 | $94K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Tyra Biosciences, Inc. (TYRA) had 7 insider filings in the last 90 days, with the most recent on 2026-06-01. The full record for TYRA runs to 44 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TYRA were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of TYRA were filed in the last 90 days. 47 sales are on record for this company.
This page tracks TYRA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TYRA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
